非布司他治疗痛风的研究进展
发布时间：2019-02-23 19:06
【摘要】：背景:痛风(gout)是嘌呤代谢紊乱引起的代谢性疾病,但痛风的发病因人而异,每个人的表现都不尽相同,除出现高尿酸血症外,在临床上还可表现为慢性关节炎、慢性间质性肾炎、急性关节炎、关节畸形、泌尿系统的尿酸性结石和痛风石。当高尿酸血症患者伴随上述临床症状时,才能诊断为痛风。治疗一般有以下几类药:排UA药、抑制UA生成药、碱性药物、秋水仙碱、非甾体抗炎药、糖皮质激素等。随着对痛风的进一步了解,近几年发现了一种新型的降尿酸药物非布司他,为黄嘌呤氧化酶(XO)抑制剂,通过抑制黄嘌呤氧化酶减少UA的生成,从而起到降低UA的作用,适用于高尿酸血症患者伴有痛风症状的长期治疗,不适合其用来治疗单纯性的高尿酸血症。目的:通过综合目前非布司他在治疗痛风方面的研究,从而为临床上更好的治疗痛风提供一些参考。方法:以 非布司他、痛风、高尿酸血症‖等关键词进行检索,找出非布司他治疗痛风的相关研究,同时对其他治疗痛风的药物进行总结。结果与结论:目前有大量有关非布司他及其他药物治疗痛风的文献,综合这些研究结果表明非布司他是目前治疗有痛风症状的高尿酸血症的首选治疗药物,非布司他的副作用较其他药物而言相对较小,在降尿酸方面目前是疗效最好的药物。
[Abstract]:Background: gout (gout) is a metabolic disease caused by purine metabolic disorder. However, the incidence of gout varies from person to person. In addition to hyperuricemia, gout is characterized by chronic arthritis. Chronic interstitial nephritis, acute arthritis, joint deformities, urinary acid stones and gout stones. Gout can only be diagnosed when hyperuricemia is accompanied by these clinical symptoms. Treatment generally has the following kinds of drugs: UA drugs, UA inhibitory drugs, alkaline drugs, colchicine, non-steroidal anti-inflammatory drugs, glucocorticoids and so on. With the further understanding of gout, in recent years, a new type of anti-uric acid drug, non-bustrast, has been discovered as a (XO) inhibitor of xanthine oxidase, which can reduce the production of UA by inhibiting xanthine oxidase, thus reducing the effect of UA. It is suitable for long-term treatment of hyperuricemia with gout symptoms and is not suitable for the treatment of simple hyperuricemia. Objective: to provide some references for better clinical treatment of gout by synthesizing the current research on the treatment of gout. Methods: to search for the key words of fenburestar, gout and hyperuricemia, to find out the related studies on the treatment of gout, and to summarize the other drugs for treating gout. Results & conclusion: there are a large number of literatures on the treatment of gout with non-buflast and other drugs. These results indicate that Festa is the first choice in the treatment of hyperuricemia with symptoms of gout. The side effects of non-busultan are relatively small compared with other drugs and are currently the most effective in reducing uric acid.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R589.7
本文编号：2429110
[Abstract]:Background: gout (gout) is a metabolic disease caused by purine metabolic disorder. However, the incidence of gout varies from person to person. In addition to hyperuricemia, gout is characterized by chronic arthritis. Chronic interstitial nephritis, acute arthritis, joint deformities, urinary acid stones and gout stones. Gout can only be diagnosed when hyperuricemia is accompanied by these clinical symptoms. Treatment generally has the following kinds of drugs: UA drugs, UA inhibitory drugs, alkaline drugs, colchicine, non-steroidal anti-inflammatory drugs, glucocorticoids and so on. With the further understanding of gout, in recent years, a new type of anti-uric acid drug, non-bustrast, has been discovered as a (XO) inhibitor of xanthine oxidase, which can reduce the production of UA by inhibiting xanthine oxidase, thus reducing the effect of UA. It is suitable for long-term treatment of hyperuricemia with gout symptoms and is not suitable for the treatment of simple hyperuricemia. Objective: to provide some references for better clinical treatment of gout by synthesizing the current research on the treatment of gout. Methods: to search for the key words of fenburestar, gout and hyperuricemia, to find out the related studies on the treatment of gout, and to summarize the other drugs for treating gout. Results & conclusion: there are a large number of literatures on the treatment of gout with non-buflast and other drugs. These results indicate that Festa is the first choice in the treatment of hyperuricemia with symptoms of gout. The side effects of non-busultan are relatively small compared with other drugs and are currently the most effective in reducing uric acid.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R589.7
【参考文献】
相关期刊论文 前6条
1 叶仿武;朱峪英;吴理扬;沈维;;非布司他对痛风患者血尿酸水平的影响[J];临床医学研究与实践;2016年08期
2 贾会欣;怀文丽;孙巍;李玲玲;;非布司他治疗前后的原发性痛风患者的超声影像学比较[J];中国现代药物应用;2016年10期
3 沈杰;周蓉;蒋茜;冯雪芳;陈闽东;;非布司他治疗慢性肾脏病4～5期合并高尿酸血症的有效性及安全性观察[J];世界临床药物;2015年11期
4 蒋兰兰;金星;沈峗;马建华;吴锦丹;;非布司他治疗痛风伴高尿酸血症患者的有效性及安全性[J];实用医学杂志;2014年17期
5 耿艳艳;于冰;徐为人;汤立达;;新型痛风治疗药物lesinuard sodium[J];现代药物与临床;2014年06期
6 郭立新;;从《高尿酸血症和痛风治疗中国专家共识》谈高尿酸血症的治疗[J];药品评价;2014年01期
，本文编号：2429110
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2429110.html
最近更新
教材专著
